Outlook Therapeutics Inc. (OTLK)
NASDAQ: OTLKHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 0.5755 -2.46%
OTLK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $143.63M
- EPS (TTM)
- -$0.70
- Dividend yield
- None
- 52-week range
- 0.161 – 2.54
- Day range
- 0.58 – 0.6066
- Volume / Avg
- 4.22M / 13.58M
- Beta
- —
- Shares outstanding
- 243.45M
52-week range
OTLK stock today
Outlook Therapeutics (OTLK) closed at $0.59 on Oct 7, up 3.15% (+$0.018), versus the S&P 500's 0.22% decline. Trading was light, with 4.22M shares changing hands, about 31% of the average daily volume. At this level, OTLK sits near the bottom of its 52-week range of $0.161 to $2.54: 76.8% below the high, set on Dec 17, 2025 and 266.5% above the low.
OTLK is down 62.7% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 49.6%. Outlook Therapeutics has posted a net loss over the last twelve months (EPS of -$0.70), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Outlook Therapeutics
Company profileOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Robert Charles Jahr
- Headquarters
- Iselin, NJ
- Employees
- 17
- IPO year
- 2016
- Website
- outlooktherapeutics.com
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$5.03+752.54%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Outlook Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVXLAnavex Life Sciences Corp. | 1.53 | -4.38% | $141.83M | vs OTLK |
| ARMPArmata Pharmaceuticals Inc. | 3.81 | -1.04% | $141.66M | vs OTLK |
| MOLNMolecular Partners AG ADR | 3.81 | +0.79% | $145.94M | vs OTLK |
| TLSATiziana Life Sciences Ltd. | 1.10 | -0.90% | $139.99M | vs OTLK |
| RNAAtrium Therapeutics Inc. | 7.93 | -0.75% | $135.65M | vs OTLK |
| ABOSAcumen Pharmaceuticals Inc. | 2.10 | +3.45% | $151.87M | vs OTLK |
| VYGRVoyager Therapeutics Inc. | 2.47 | +0.41% | $152.20M | vs OTLK |
| CLLSCellectis S.A. ADR | 1.34 | -4.29% | $134.96M | vs OTLK |
Indexes, lists and sector
Appears in lists
Outlook Therapeutics stock FAQ
What is Outlook Therapeutics's stock price today?
OTLK last traded at $0.59 as of Oct 7, 4:00 PM EDT, up 3.15% on the day. Prices are delayed at least 15 minutes.
Does Outlook Therapeutics pay a dividend?
No. Outlook Therapeutics does not currently pay a regular cash dividend.
Who is Outlook Therapeutics's CEO?
Mr. Robert Charles Jahr is the chief executive officer of Outlook Therapeutics Inc., which has about 17 employees.
Has OTLK ever split its stock?
Yes. The most recent OTLK stock split was a 1-for-20 split on Mar 14, 2024, one of 2 splits on record.
What is the OTLK 52-week high?
The 52-week high for OTLK is $2.54 and the 52-week low is $0.161. The stock is currently 76.8% below its high.